Pragati Maidan to witness Mega Health & Wellness Exposition this weekend

New Delhi: The Namo Gange Trust’s flagship Yogshala Expo is gaining enormous traction among health and wellness seekers. Its 3 day 3rd edition in Pragati Maidan starting from May 4 is billed to be a mega one reflecting Yoga’s fast growing popularity.

Talking to Medicare News, Nirmal Vaid, Chief Patron, Namo Gange Trust, said, ‘Yoga needs to be made to be part of everyone’s life in India to realize the aim of Healthy India. Our flagship instrument The Yogashala Expo is doing all efforts to this end. For 3 rd edition we are looking forward to a huge draw of people.’

Mr Vaid further said, ‘We are expecting an enormous footfall of nearly 25’000 to 30’000. There would be 80-100 exhibitors and around 50 health & wellness activities including workshops, seminars, free health pavilion, live performances, spot paintings, and contests.’

The Yogshala Expo 2018″, scheduled to be held from May 04 to May 06, 2018 at Hall No 7, in Pragati Maidan. In comparison to earlier editions, the Yogshala Expo 2018 is undoubtedly going to be one of the biggest health and wellness carnivals ever witnessed in the national capital. The Yogshala Expo 2018 as the full spectrum of ‘Health & Wellness’, would be showcasing, various products and services allied to Yoga, Ayurveda, Naturopathy, Homeopathy, Unani, Siddha and Herbal. It also includes focused topics and subjects such as Organic Farming, Organic Products, Food Supplements, Diet, Nutrition, Health Retreats, Spas, Hospitals, Labs, Academics, R & D Institutes, Bioenergy Products & Manufacturers, Bio-Medicine Producers, Medicinal Plants, Biological Clothing and other lifestyle products and services. The Yogshala Expo is aimed to support world health and to create global acceptance for alternative, traditional and complimentary medicines.

The Namo Gange Trust is a non-profit organization, founded with a vision to serve diverse extensions of ‘World Family’ through dedicated services and activities. We are working for the upliftment of incapacitated, backward and rural communities through various activities and awareness programs related to health, wellness, education and culture.

  • Related Posts

    Lilly launches Mounjaro KwikPen in India

    Mumbai, August 14, 2025 — Eli Lilly and Company (India) has rolled out the Mounjaro (tirzepatide) KwikPen across the country, expanding treatment choices for people with type-2 diabetes and those…

    Fortis Q1 Profit Jumps 57%; Expansion Drives Growth

      Gurugram, August 7 – http://Fortis HealthcareFortis Healthcare has reported a 57% year-on-year increase in its net profit for the first quarter of FY2025. The hospital chain posted ₹260 crore…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Centre bans fixed-dose combination for Common Cold in children below four

    Centre bans fixed-dose combination for Common Cold in children below four

    New research study proposes a unifying theory for Alzheimer’s disease and other neurodegenerative diseases

    New research study proposes a unifying theory for Alzheimer’s disease and other neurodegenerative diseases

    Brain organoid maturation is driven by a lifelike developmental clock: Study

    Brain organoid maturation is driven by a lifelike developmental clock: Study

    Delhi Police Bust ₹9-Crore Interstate Cancer Drug Diversion Network: 17 Arrested; 588 Anti-Cancer Vials, ₹50 Lakh Cash Seized

    Delhi Police Bust ₹9-Crore Interstate Cancer Drug Diversion Network: 17 Arrested; 588 Anti-Cancer Vials, ₹50 Lakh Cash Seized

    ‘Smart’ Cancer Drug RK-251 Developed by Indian Scientists Could Offer Targeted Alternative to Chemotherapy

    ‘Smart’ Cancer Drug RK-251 Developed by Indian Scientists Could Offer Targeted Alternative to Chemotherapy

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses